文献速递胃肠动力与功能性疾病

基于微生物组的人工智能辅助个性化饮食与低可发酵寡糖、二糖、单糖和多元醇饮食治疗肠易激综合征的多中心随机对照试验:一种新方法

A Multicenter Randomized Controlled Trial of Microbiome-Based Artificial Intelligence-Assisted Personalized Diet vs Low-Fermentable Oligosaccharides, Disaccharides, Monosaccharides, and Polyols Diet: A Novel Approach for the Management of Irritable Bowel Syndrome.
PubMed 文献 · Am J Gastroenterol · 2024-05-08

这项多中心随机对照试验纳入121例肠易激综合征(IBS)患者,70例接受基于微生物组的人工智能辅助个性化饮食(PD),51例接受低可发酵寡糖、二糖、单糖和多元醇饮食(FODMAP),干预均为6周。主要结局为两组间IBS症状严重程度量表(IBS-SSS)的个体内差值,PD组变化为-112.7,FODMAP饮食组为-99.9(P=0.29)。PD在改善症状、生活质量及微生物组多样性方面显示出潜力。

要点

  • PD组与FODMAP饮食组IBS-SSS变化分别为-112.7与-99.9,组间比较P=0.29。
  • 两组IBS-SSS总分、频率、腹胀及生活干扰均较基线显著改善(P<0.001)。
  • PD干预后微生物组多样性发生显著变化(P<0.05),并与FODMAP饮食组存在分类群差异。

核心结论

  • 人工智能辅助的个性化饮食 emerges as a promising approach for comprehensive IBS management,可显著缓解症状、改善生活质量并引起肠道微生物组多样性变化。

研究设计与样本

  • 多中心随机对照试验,共纳入121例IBS患者,PD组70例,FODMAP饮食组51例,两种干预均持续6周。

主要发现

  • 主要结局IBS-SSS个体内变化:PD组-112.7 vs FODMAP饮食组-99.9(P=0.29)。
  • 两组IBS-SSS总分、频率、腹胀及生活干扰均显著改善(P<0.001)。
  • 两组焦虑水平及IBS生活质量(IBS-QOL)评分均显著改善(P<0.001)。
  • PD在IBS-C(P<0.001)、IBS-D(P=0.01)和IBS-M(P<0.001)各亚型中均有效降低IBS-SSS评分;FODMAP饮食在IBS-C(P=0.004)和IBS-M(P<0.001)中有 comparable improvements。
  • PD干预显著改善所有亚型的IBS-QOL评分(IBS-C P<0.001,IBS-D P<0.001,IBS-M P=0.008);FODMAP饮食仅改善IBS-C(P=0.004)和IBS-D(P=0.022)的IBS-QOL评分。

局限性

  • 原文未报告局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

INTRODUCTION: Personalized management strategies are pivotal in addressing irritable bowel syndrome (IBS). This multicenter randomized controlled trial focuses on comparing the efficacy of a microbiome-based artificial intelligence-assisted personalized diet (PD) with a low-fermentable oligosaccharides, disaccharides, monosaccharides, and polyols diet (FODMAP) for IBS management. METHODS: One hundred twenty-one patients participated, with 70 assigned to the PD group and 51 to the FODMAP diet group. IBS subtypes, demographics, symptom severity (IBS-SSS), anxiety, depression, and quality of life (IBS-QOL) were evaluated. Both interventions spanned 6 weeks. The trial's primary outcome was the within-individual difference in IBS-SSS compared between intervention groups. RESULTS: For the primary outcome, there was a change in IBS-SSS of -112.7 for those in the PD group vs -99.9 for those in the FODMAP diet group ( P = 0.29). Significant improvement occurred in IBS-SSS scores ( P < 0.001), frequency ( P < 0.001), abdominal distension ( P < 0.001), and life interference ( P < 0.001) in both groups. In addition, there were significant improvements in anxiety levels and IBS-QOL scores for both groups ( P < 0.001). Importantly, PD was effective in reducing IBS SSS scores across all IBS subtypes IBS-Constipation (IBS-C; P < 0.001), IBS-Diarrhea (IBS-D; P = 0.01), and IBS-Mixed (IBS-M; P < 0.001) while FODMAP diet exhibited comparable improvements in IBS-C ( P = 0.004) and IBS-M ( P < 0.001). PD intervention significantly improved IBS-QOL scores for all subtypes (IBS-C [ P < 0.001], IBS-D [ P < 0.001], and IBS-M [ P = 0.008]) while the FODMAP diet did so for the IBS-C ( P = 0.004) and IBS-D ( P = 0.022). Notably, PD intervention led to significant microbiome diversity shifts ( P < 0.05) and taxa alterations compared with FODMAP diet. DISCUSSION: The artificial intelligence-assisted PD emerges as a promising approach for comprehensive IBS management. With its ability to address individual variation, the PD approach demonstrates significant symptom relief, enhanced QOL, and notable diversity shifts in the gut microbiome, making it a valuable strategy in the evolving landscape of IBS care.

来源:Am J Gastroenterol,查看原文。版权归原作者所有。

引用

  1. Tunali V, Arslan NÇ, Ermiş BH, et al. A Multicenter Randomized Controlled Trial of Microbiome-Based Artificial Intelligence-Assisted Personalized Diet vs Low-Fermentable Oligosaccharides, Disaccharides, Monosaccharides, and Polyols Diet: A Novel Approach for the Management of Irritable Bowel Syndrome. Am J Gastroenterol. 2024. PMID: 38717025. doi:10.14309/ajg.0000000000002862

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。